Sickle Cell Disease Clinical Trial
Official title:
Measurement of the Reactive Hyperemia Index in Sickle Cell Patients During Pain Crisis and After Recovery
Background:
- Many people with sickle cell disease have repeated episodes of severe pain that lasts for
days, requiring hospital care. These episodes, called pain crises, may be caused by changes
in blood flow. Researchers want to study blood flow in people with sickle cell disease who
are having a pain crisis and compare it with their blood flow after the pain crisis has
resolved. They also want to compare these measurements against blood flow in healthy people
who do not have sickle cell disease.
Objectives:
- To study whether changes in blood flow cause pain crises in people with sickle cell
disease.
Eligibility:
- Individuals at least 18 years of age who have sickle cell disease and are being treated
for a pain crisis.
- Individuals at least 18 years of age who have sickle cell disease and are not
experiencing a pain crisis.
- Healthy volunteers matched by age and gender with the participants who have sickle cell
disease.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected.
- Participants having a sickle cell pain crisis will have two visits, one during the
crisis and one about 4 weeks after the crisis has resolved.
- Participants not having a sickle cell pain crisis will have one or two study visits.
Blood samples will be collected during at least one of these visits.
- Healthy volunteers will have one or two study visits. Blood samples will be collected
during at least one of these visits.
- During each visit for all participants, cameras and blood flow monitoring equipment will
be used to measure blood flow in the forearm.
sickle cell disease.
Severe recurrent pain is the most common cause of acute morbidity in sickle cell disease1.
The underlying pathogenesis was initially thought to be ischemia from obstruction of
capillary beds by stiffened red blood cells; however, there is evidence that other factors
contribute to the pathogenesis of sickle cell pain crisis, such as inflammation and
coagulation, ischemia-reperfusion injury, angiogenesis balance, and vasomotor tone processes
that are regulated by endothelial nitric oxide.
Recent clinical data suggest that subjects with sickle cell disease suffer from chronically
impaired nitric oxide bioavailability. This has been attributed to increased consumption of
nitric oxide by hemoglobin and reactive oxygen species, or decreased production of nitric
oxide by endothelial cells; however the roles of nitric oxide bioavailability and endothelial
dysfunction during acute pain crisis are controversial and incompletely understood. Although
there have been several studies of endothelial function in steady state sickle cell disease,
there has been no comprehensive study of endothelial function during pain crisis.
In this study, our primary objective is to measure the reactive hyperemia index (a measure of
the endothelial response to shear stress) in twenty sickle cell subjects during acute pain
crisis and to compare it with the reactive hyperemia index measured after recovery from pain
crisis. This will identify whether there are acute changes in endothelial cell function
during sickle cell pain crisis. Our secondary objective is to compare the reactive hyperemia
index of thirty-five sickle cell subjects in steady state versus the reactive hyperemia index
of thirty-five healthy control subjects. This will identify whether there are chronic
differences in endothelial function between sickle cell subjects and healthy control
subjects.
This study will determine if there are defects in endothelium-dependent vasodilation in
response to shear stress during sickle cell pain crisis. Moreover, this study provides an
opportunity to evaluate new physiologic biomarkers of sickle cell pain crisis based on
measurements of blood flow, temperature, and oxygenation in the skin. These measurements may
serve as clinical endpoints in future studies of disease pathogenesis or therapeutic
interventions for sickle cell disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 |